Alport Syndrome
An inherited disease of type IV collagen causing progressive kidney failure, deafness, and eye problems.
Emergency Management: Severe hypertension or uremic complications related to advancing renal failure.
A genetic disorder characterized by progressive kidney disease, sensorineural hearing loss, and ocular abnormalities due to mutations in type IV collagen genes.
Detailed Overview
Type IV collagen is a crucial structural component of basement membranes in the glomeruli, inner ear, and eye. Defects lead to hematuria, proteinuria, and eventual end-stage renal disease (ESRD), typically in young adult males in the X-linked form.
Epidemiology & Demographics
Estimated prevalence of 1 in 50,000 live births. X-linked form accounts for 80% of cases, severely affecting males.
Etiological Mechanism
Mutations in COL4A3, COL4A4, or COL4A5 genes.
Primary Causes
Genetic inheritance: X-linked (COL4A5), autosomal recessive, or autosomal dominant (COL4A3/COL4A4).
Defective alpha-3, 4, or 5 chains of type IV collagen lead to an abnormally thin, then progressively thickened and split glomerular basement membrane (GBM). This structural failure allows red blood cells and protein to leak into urine and triggers progressive glomerulosclerosis and tubulointerstitial fibrosis.
Diagnostic Criteria & Guidelines
Hematuria plus family history of Alport/ESRD, characteristic ocular signs, sensorineural deafness, and definitive GBM changes on renal biopsy (lamellation/splitting on electron microscopy) or identification of COL4A3/4/5 mutations via genetic testing.
Renin-angiotensin-aldosterone system (RAAS) blockade: ACE inhibitors (e.g., Ramipril or Lisinopril starting at 2.5-5 mg daily, titrated up) or ARBs (e.g., Losartan) to reduce intraglomerular pressure, reduce proteinuria, and delay progression to ESRD.
Second-Line & Adjunctive Therapy
SGLT2 inhibitors (e.g., Dapagliflozin 10 mg daily) are increasingly used off-label as adjuncts to RAAS blockade to further slow renal decline.
Surgical & Procedural Management
Kidney transplantation is the treatment of choice for ESRD. Dialysis is used as a bridge.
Patient Counseling & Advice
Explain the X-linked inheritance pattern (if applicable) and offer genetic counseling for family planning. Warn about the small risk (~3%) of developing anti-GBM disease post-transplant.
Follow-Up & Monitoring Schedule
Routine screening (every 6-12 months) of blood pressure, urinalysis, urine protein-to-creatinine ratio (UPCR), eGFR, and annual audiometry and ophthalmology exams.
Preventive Strategies
Cannot be prevented. Early RAAS blockade initiation delays ESRD onset.
Untreated X-linked males usually reach ESRD by age 20-30. Early treatment delays ESRD by 10-15 years. Females with X-linked Alport have a milder course but can reach ESRD later in life.